Compare DUOT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | OBIO |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.3M | 237.2M |
| IPO Year | N/A | N/A |
| Metric | DUOT | OBIO |
|---|---|---|
| Price | $9.73 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 213.0K | 209.1K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,026,308.00 | $2,818,000.00 |
| Revenue This Year | $286.66 | $36.66 |
| Revenue Next Year | $44.93 | $2.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 159.00 | 6.46 |
| 52 Week Low | $3.84 | $2.20 |
| 52 Week High | $12.17 | $6.16 |
| Indicator | DUOT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 46.60 |
| Support Level | $10.30 | $3.46 |
| Resistance Level | $11.38 | $4.21 |
| Average True Range (ATR) | 0.69 | 0.31 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 19.08 | 43.15 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.